FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations (NCT06669117)
A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Who can join: Review the eligibility criteria below.
Location: Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
- Gabrail Cancer Research Center — Canton, Ohio
- Sarah Cannon Research Institute Oncology Partners — Nashville, Tennessee
- Institut Jules Bordet — Anderlecht,
- APHP de Marseille - Hôpital Nord — Marseille,
- Institut de Cancerologie de Ouest (ICO) - Saint-Herblain — Saint-Herblain,
- Institut Universitaire du Cancer de Toulouse - Oncopole — Toulouse,
- Gustave Roussy — Villejuif,
- Universitaet zu Koeln - Centrum fuer Integrierte Onkologie (CIO) — Cologne,
- Universitätsklinikum Carl Gustav Carus Dresden — Dresden,
- Azienda Ospedaliero - Universitaria San Luigi Gonzaga — Orbassano,
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis — Amsterdam,
- Yonsei University College of Medicine — Seoul,
- Asan Medical Center (AMC) — Seoul,
- Hospital Universitario 12 de Octubre — Madrid,
- Hospital Universitario La Paz — Madrid,
- National Taiwan University Hospital — Taipei,
- Taipei Medical University Hospital — Taipei,
- Taipei Veterans General Hospital — Taipei,
📞 Contact the Study Coordinator
Phone: +33 684 66 43 48
Email: yuhua.wang@pierre-fabre.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.